Trial Profile
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Adenocarcinoma; Carcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRITON2
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 08 Mar 2024 This trial has been competed in Italy, according to European Clinical Trials Database record.
- 15 Aug 2023 Final results from the Phase 2 TRITON2 Study published in the European Urology
- 01 Mar 2023 Results (n=100) assessing the prevalence of BRCA reversion mutations in the plasma of patients with BRCA+ mCRPC after progression on rucaparib published in the European Urology.